Home
About Us
Who We Are
Our Niche
Our Results
Recent Placements
Replacement Policy
Our Brochures
Our Team
Hot Jobs
Search Services
Search Services
Diversity & Inclusion
Code of Ethics
Awards & Recognitions
Career Coaching
Resources
Recruiter Tips
News and Insights
Resume Resources
Working From Home
My Inspirement
Healthy Living for Executives
Testimonials
AI Training and Quality Disclosure
Contact Us

The Bandish Group

Home
About Us
Who We Are
Our Niche
Our Results
Recent Placements
Replacement Policy
Our Brochures
Our Team
Hot Jobs
Search Services
Search Services
Diversity & Inclusion
Code of Ethics
Awards & Recognitions
Career Coaching
Resources
Recruiter Tips
News and Insights
Resume Resources
Working From Home
My Inspirement
Healthy Living for Executives
Testimonials
AI Training and Quality Disclosure
Contact Us
Jackie Bandish
February 10, 2021

TG Therapeutics receives FDA approval

Jackie Bandish
February 10, 2021

TG Therapeutics has announced that it has received an accelerated FDA approval for Ukoniq (umbralisib) used to treat for two types of blood cancer.

Adam Waldman, TG Therapeutics CCO, said they will release a new, once-daily oral medication next week at a cost of $15,900 for a 30-day supply.

Click here to read the entire article.

Newer PostAnticipated launces in 2021
Older PostPackaging error triggers recall
Back to Top
Home
About Us
Who We Are
Our Niche
Our Results
Recent Placements
Replacement Policy
Our Brochures
Our Team
Hot Jobs
Search Services
Search Services
Diversity & Inclusion
Code of Ethics
Awards & Recognitions
Career Coaching
Resources
Recruiter Tips
News and Insights
Resume Resources
Working From Home
My Inspirement
Healthy Living for Executives
Testimonials
AI Training and Quality Disclosure
Contact Us
The Bandish Group, LLC, Bucks County, PA267-483-5233info@bandishgroup.com

Headquarters: Greater Philadelphia Area